A cancer that starts in the kidney's cells is called kidney cancer. A cancer that starts in the kidneys is called kidney cancer. The two bean-shaped organs known as kidneys are each roughly the size of a fist. With one kidney on each side of the spine, they are situated behind the abdominal organs. One of the most prevalent kinds of kidney cancer in adults is renal cell carcinoma (RCC). Surgery to remove the kidney is done to treat kidney cancer when it has advanced to the point where it is essential to remove the malignant cells. The laparoscopic removal of the tumor-affected region has taken the position of this therapy approach. Tumors are often treated with medications in advanced stages of the illness.
The market for pharmaceuticals to treat Kidney Cancer is anticipated to reach US$ 5.83 billion in 2022 and grow at a 6.4% CAGR during the next five years (2022-2030).
Prominent Companies in the Kidney Cancer Drugs Industry:
1. Pfizer Inc.
Pfizer Inc. (Pfizer), a business founded in 1849, finds, develops, produces, and sells biopharmaceuticals. The business sells goods to cure a range of ailments, including cancer, inflammation, rare illnesses, metabolic, cardiovascular, and metabolic and pain problems, as well as women's health issues. Moreover, it offers contract manufacturing services, sterile injectable drugs, biosimilars, active pharmaceutical ingredients (APIs), and medicines. Pfizer offers its goods through distributors, merchants, pharmacies, hospitals, private physician offices, clinics, and public institutions. India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US are all home to significant production facilities for it. The firm ships its goods to Europe, Africa, the Middle East, Asia-Pacific, Australia, and North and South America. In the US, New York serves as the home of Pfizer.
2. Novartis.
One of the biggest pharmaceutical firms in the world, Novartis ranked fourth in terms of sales in 2022. Novartis AG (Novartis), a healthcare organisation founded in February 1996, focused on the research, production, and marketing of prescription and over-the-counter pharmaceutical goods, as well as products for eye care. In addition to others, it offers medicines for the treatment of solid tumours, immunological disorders, infections, cardiovascular illness, dermatological issues, neurological disorders, ophthalmic and respiratory diseases, cancer, and neurological disorders. Via Sandoz, the business provides biosimilars and generic medications. With The Novartis Institutes for BioMedical Research, Novartis carries out research in a number of illness areas (NIBR). Across the Americas, Europe, the Middle East, Africa, and Asia-Pacific, the corporation has a network of subsidiaries and offices.Basel, Switzerland serves as the headquarters of Novartis.
3. Genentech Inc.
Genentech, Inc., an American biotechnology company with its headquarters in South San Francisco, California, was established in 1976. In 2009, it was transformed into a separate Roche business. Within Roche, Genentech Research and Early Development functions as a separate centre. Leading biotechnology business Genentech is committed to pioneering research in order to find and provide medications for patients with serious and life-threatening illnesses. The first targeted antibody for cancer and the first treatment for primary progressive multiple sclerosis are only two of its groundbreaking breakthroughs.
The organization's main office is in South San Francisco, California, USA. More than 2,400 people work there. Lunsumio, a first-in-class bispecific antibody from Genentech, has received FDA approval for the treatment of relapsed or resistant follicular lymphoma.
4. Active Biotech AB .
Active Biotech AB, a biotechnology business founded in 1998, uses its vast knowledge base and portfolio of drugs to create first-in-class immunomodulatory medicines for specialised cancer and immunology diseases with high unmet medical need and promising commercial potential. After a portfolio refocus, Active Biotech's business approach aims to get ideas through the clinical development phase before continuing to develop the programmes either independently or in collaboration. Three projects are presently part of Active Biotech's portfolio: Tasquinimod and Laquinimod, two wholly-owned small molecule immunomodulators with a method of action that involves modulating myeloid immune cell activity, are respectively aimed against haematological malignancies and inflammatory ocular conditions.